{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:16:29Z","timestamp":1788218189257,"version":"build-2803163510"},"reference-count":55,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Background\/Objectives: Lichen planus (LP) is a chronic inflammatory disease of autoimmune origin, affecting the skin and mucous membranes. While corticosteroids and immunosuppressants are traditionally used, many cases remain refractory or intolerant to standard therapies. Recent advances in immunopathogenesis have led to the exploration of targeted therapies, including biologic agents and small-molecule inhibitors. Methods: This review synthesizes current evidence from case reports, case series, and observational studies on the use of monoclonal antibodies (anti-TNF-\u03b1, anti-IL-17, anti-IL-23, anti-IL-6) and JAK inhibitors in LP. A structured literature search was conducted across PubMed, Scopus, and Web of Science, focusing on studies published between 2010 and 2025. Data on mechanisms, clinical efficacy, safety, and research limitations were extracted and summarized. Results: Promising therapeutic responses were reported for IL-17 inhibitors (secukinumab, ixekizumab) and JAK inhibitors (tofacitinib, baricitinib) in mucosal and recalcitrant LP. Anti-TNF agents showed variable efficacy, while emerging targets such as BTK and IFN-\u03b3 are under investigation. Adverse events were generally mild to moderate, but long-term safety data are lacking. The absence of randomized controlled trials and standardized outcome measures limits generalizability. Conclusions: Biologic and small-molecule therapies represent a potential paradigm shift in the treatment of LP, offering targeted immunomodulation with promising efficacy in refractory cases. Further collaborative research, including randomized studies and biomarker-driven approaches, is urgently needed to validate these treatments and establish personalized care strategies.<\/jats:p>","DOI":"10.3390\/antib14030079","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T13:03:02Z","timestamp":1758114182000},"page":"79","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Monoclonal Antibodies and Small-Molecule Therapies for Lichen Planus: Targeted Immunomodulation and Emerging Evidence"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1655-0395","authenticated-orcid":false,"given":"Francois","family":"Rosset","sequence":"first","affiliation":[{"name":"School of Dermatology and Venereology, Department of Medical Sciences, University of Turin, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Sciamarrelli","sequence":"additional","affiliation":[{"name":"School of Dermatology and Venereology, Department of Medical Sciences, University of Turin, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-3219","authenticated-orcid":false,"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[{"name":"School of Dermatology and Venereology, Department of Medical Sciences, University of Turin, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3504-2417","authenticated-orcid":false,"given":"Valentina","family":"Pala","sequence":"additional","affiliation":[{"name":"School of Dermatology and Venereology, Department of Medical Sciences, University of Turin, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Boskovic","sequence":"additional","affiliation":[{"name":"School of Dermatology and Venereology, Department of Medical Sciences, University of Turin, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1915-9993","authenticated-orcid":false,"given":"Eleonora","family":"Bongiovanni","sequence":"additional","affiliation":[{"name":"School of Dermatology and Venereology, Department of Medical Sciences, University of Turin, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9270-1204","authenticated-orcid":false,"given":"Orsola","family":"Crespi","sequence":"additional","affiliation":[{"name":"School of Dermatology and Venereology, Department of Medical Sciences, University of Turin, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Liao","sequence":"additional","affiliation":[{"name":"School of Dermatology and Venereology, Department of Medical Sciences, University of Turin, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-1406","authenticated-orcid":false,"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[{"name":"School of Dermatology and Venereology, Department of Medical Sciences, University of Turin, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"School of Dermatology and Venereology, Department of Medical Sciences, University of Turin, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"737813","DOI":"10.3389\/fmed.2021.737813","article-title":"Lichen Planus","volume":"8","author":"Boch","year":"2021","journal-title":"Front. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"742826","DOI":"10.1155\/2014\/742826","article-title":"Cutaneous and mucosal lichen planus: A comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis","volume":"2014","author":"Gorouhi","year":"2014","journal-title":"Sci. World J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.clindermatol.2015.05.001","article-title":"Lichen planus and lichenoid reactions as a systemic disease","volume":"33","author":"Schliemann","year":"2015","journal-title":"Clin. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamadermatol.2019.3797","article-title":"Global Prevalence and Incidence Estimates of Oral Lichen Planus: A Systematic Review and Meta-analysis","volume":"156","author":"Li","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40257-023-00814-3","article-title":"Oral Lichen Planus: An Update on Diagnosis and Management","volume":"25","author":"Louisy","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Vi\u010di\u0107, M., Hla\u010da, N., Ka\u0161telan, M., Brajac, I., Soto\u0161ek, V., and Prpi\u0107 Massari, L. (2023). Comprehensive Insight into Lichen Planus Immunopathogenesis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24033038"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/odi.14142","article-title":"Immune mechanisms in oral lichen planus","volume":"29","author":"Thornhill","year":"2023","journal-title":"Oral Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"eaav7561","DOI":"10.1126\/scitranslmed.aav7561","article-title":"IFN-\u03b3 enhances cell-mediated cytotoxicity against keratinocytes via JAK2\/STAT1 in lichen planus","volume":"11","author":"Shao","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/exd.14226","article-title":"The inflammation in cutaneous lichen planus is dominated by IFN-\u03d2 and IL-21\u2014A basis for therapeutic JAK1 inhibition","volume":"30","author":"Pietschke","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3389\/fimmu.2019.01808","article-title":"Therapeutic Targeting of Th17\/Tc17 Cells Leads to Clinical Improvement of Lichen Planus","volume":"10","author":"Solimani","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Serafini, G., De Biase, A., Lamazza, L., Mazzucchi, G., and Lollobrigida, M. (2023). Efficacy of Topical Treatments for the Management of Symptomatic Oral Lichen Planus: A Systematic Review. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20021202"},{"key":"ref_12","first-page":"CD001168","article-title":"Interventions for treating oral lichen planus: Corticosteroid therapies","volume":"2020","author":"Lodi","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1279220","DOI":"10.3389\/fcimb.2024.1279220","article-title":"What can we learn from treatments of oral lichen planus?","volume":"14","author":"Wu","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40257-024-00878-9","article-title":"Lichen Planus: What is New in Diagnosis and Treatment?","volume":"25","author":"Tekin","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Nukaly, H.Y., Halawani, I.R., Alghamdi, S.M.S., Alruwaili, A.G., Binhezaim, A., Algahamdi, R.A.A., Alzahrani, R.A.J., Alharamlah, F.S.S., Aldumkh, S.H.S., and Alasqah, H.M.A. (2024). Oral Lichen Planus: A Narrative Review Navigating Etiologies, Clinical Manifestations, Diagnostics, and Therapeutic Approaches. J. Clin. Med., 13.","DOI":"10.3390\/jcm13175280"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"997190","DOI":"10.3389\/fmed.2022.997190","article-title":"Therapeutic strategies for oral lichen planus: State of the art and new insights","volume":"9","author":"Didona","year":"2022","journal-title":"Front. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamadermatol.2023.4889","article-title":"Oral Acitretin Plus Topical Triamcinolone vs Topical Triamcinolone Monotherapy in Patients with Symptomatic Oral Lichen Planus: A Randomized Clinical Trial","volume":"160","author":"Vinay","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/bjd\/ljae181","article-title":"Secukinumab in adult patients with lichen planus: Efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study","volume":"191","author":"Passeron","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e179436","DOI":"10.1172\/JCI179436","article-title":"Rapid response of lichen planus to baricitinib associated with suppression of cytotoxic CXCL13+CD8+ T cells","volume":"135","author":"Hwang","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2008.09.032","article-title":"Lichen planus-like eruptions: An emerging side effect of tumor necrosis factor-\u03b1 antagonists","volume":"61","author":"Asarch","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","first-page":"CD008092","article-title":"Interventions for erosive lichen planus affecting mucosal sites","volume":"2012","author":"Cheng","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_23","first-page":"981","article-title":"Individualisierte behandlung und therapiewahl bei lichen planus: Ein schrittweiser ansatz","volume":"11","author":"Manousaridis","year":"2013","journal-title":"JDDG\u2014J. Ger. Soc. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1111\/jdv.15771","article-title":"Lichen planus: A comprehensive evidence-based analysis of medical treatment","volume":"33","author":"Gieler","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0140-6736(24)01750-1","article-title":"IL-23 inhibition for chronic inflammatory disease","volume":"404","author":"Jairath","year":"2024","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.smim.2014.01.009","article-title":"A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy","volume":"26","author":"Tanaka","year":"2014","journal-title":"Semin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e14990","DOI":"10.1111\/dth.14990","article-title":"Does tocilizumab have a role in dermatology? A review of clinical applications, its adverse side effects and practical considerations","volume":"34","author":"Choong","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/intimm\/dxu081","article-title":"Therapeutic uses of anti-interleukin-6 receptor antibody","volume":"27","author":"Kang","year":"2015","journal-title":"Int. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra therapy for non-cancer inflammatory diseases","volume":"9","author":"Cavalli","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"888392","DOI":"10.3389\/fimmu.2022.888392","article-title":"Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders","volume":"13","author":"Arnold","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/bjd.20975","article-title":"Therapeutic potential of targeting interleukin-1 family cytokines in chronic inflammatory skin diseases","volume":"186","author":"Calabrese","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaci.2021.08.010","article-title":"The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions","volume":"148","author":"Fragoulis","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Taylor","year":"2024","journal-title":"Rheumatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"106362","DOI":"10.1016\/j.phrs.2022.106362","article-title":"Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders","volume":"183","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3899\/jrheum.2023-0145","article-title":"Safety of Janus Kinase Inhibitors: A Real-World Multicenter Retrospective Cohort Study","volume":"50","author":"Lanzillotta","year":"2023","journal-title":"J. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1023213","DOI":"10.3389\/fimmu.2022.1023213","article-title":"Updates on immunological mechanistic insights and targeting of the oral lichen planus microenvironment","volume":"13","author":"Deng","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00403-024-02838-z","article-title":"Assessment of PD-1 and PD-L1 tissue expression levels in lichen planus patients: A case\u2013control study","volume":"316","author":"Elmasry","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/1346-8138.15977","article-title":"Reduced expression of programmed cell death 1 and programmed cell death ligand 1 in infiltrating inflammatory cells of lichen planus without administration of immune checkpoint inhibitors","volume":"48","author":"Shirouchi","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti\u2013Programmed Cell Death 1 and Anti\u2013Programmed Cell Death Ligand 1 Immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e15432","DOI":"10.1111\/dth.15432","article-title":"Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab","volume":"35","author":"Shah","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/DAD.0000000000000688","article-title":"Lichenoid Dermatologic Toxicity from Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features","volume":"39","author":"Tetzlaff","year":"2017","journal-title":"Am. J. Dermatopathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/cup.14299","article-title":"Lichen-planus-pemphigoides-like reaction to PD-1 checkpoint blockade","volume":"49","author":"Wat","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41586-023-06217-y","article-title":"PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens","volume":"619","author":"Damo","year":"2023","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/DAD.0000000000002139","article-title":"Lichen Planus Pemphigoides Associated with PD-1 and PD-L1 Inhibitors: A Case Series and Review of the Literature","volume":"44","author":"Boyle","year":"2022","journal-title":"Am. J. Dermatopathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1111\/all.15261","article-title":"Bruton\u2019s tyrosine kinase inhibition\u2014An emerging therapeutic strategy in immune-mediated dermatological conditions","volume":"77","author":"Brasileiro","year":"2022","journal-title":"Allergy Eur. J. Allergy Clin. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1080\/14656566.2024.2393280","article-title":"The potential of Bruton\u2019s tyrosine kinase (BTK) inhibitors in the pharmacotherapeutic management of immune and dermatological disease","volume":"25","author":"Tseng","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Robak, E., and Robak, T. (2022). Bruton\u2019s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives. J. Clin. Med., 11.","DOI":"10.37247\/PAMED4ED.4.22.14"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Rozkiewicz, D., Hermanowicz, J.M., Kwiatkowska, I., Krupa, A., and Pawlak, D. (2023). Bruton\u2019s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials. Molecules, 28.","DOI":"10.3390\/molecules28052400"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tips.2024.06.006","article-title":"BTK inhibitors: Past, present, and future","volume":"45","author":"Cool","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s40265-021-01592-0","article-title":"Bruton\u2019s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease","volume":"81","author":"Neys","year":"2021","journal-title":"Drugs"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zhang, D., Gong, H., and Meng, F. (2021). Recent advances in btk inhibitors for the treatment of inflammatory and autoimmune diseases. Molecules, 26.","DOI":"10.3390\/molecules26164907"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e1021","DOI":"10.1111\/jdv.18427","article-title":"Impact of comorbidities in the response of atopic patients treated with dupilumab: A real-life study up to 36 weeks","volume":"36","author":"Mastorino","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e15115","DOI":"10.1111\/dth.15115","article-title":"Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real-life study","volume":"34","author":"Mastorino","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"449","DOI":"10.23736\/S2784-8671.21.07070-5","article-title":"Lichen ruber planus arising during dupilumab treatment for atopic dermatitis","volume":"157","author":"Mastorino","year":"2022","journal-title":"Ital. J. Dermatol. Venereol."}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/14\/3\/79\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:47:03Z","timestamp":1760035623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/14\/3\/79"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["antib14030079"],"URL":"https:\/\/doi.org\/10.3390\/antib14030079","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}